Treatment of Myasthenia Gravis
- 4 January 1973
- journal article
- review article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 288 (1) , 27-31
- https://doi.org/10.1056/nejm197301042880107
Abstract
THE therapy of myasthenia gravis is one of the more challenging but often also one of the most rewarding forms of drug therapy encountered by the physician. Myasthenia is a chronic disease characterized by skeletal-muscle weakness that may range in severity from slight depression of maximal strength to complete motor failure. These extremes of functional impairment may be seen at different times in the same patient. Any muscle may be affected. Thus, the functional impairment ranges from slight ptosis to complete respiratory failure. The course of the disease is highly variable, and prognosis is uncertain. The goal of drug therapy . . .Keywords
This publication has 6 references indexed in Scilit:
- Corticotrophin therapy in myasthenia gravisNeurology, 1971
- THE USE OF ACTH AND CORTICOSTEROIDS IN MYASTHENIA GRAVISAnnals of the New York Academy of Sciences, 1971
- MYASTHENIA GRAVIS AND MYASTHENIC SYNDROMES TREATED WITH PREDNISONEActa Neurologica Scandinavica, 1971
- GERMINE MONO- AND DIACETATE IN MYASTHENIA GRAVISAnnals of the New York Academy of Sciences, 1971
- Metabolism of 14 C‐labeled pyridostigmine in myasthenia gravisNeurology, 1970
- Myasthenia gravisNeurology, 1966